Medical aesthetics industry giants have confirmed that facial fat loss caused by GLP-1 weight loss drugs (such as Novo Nordisk's semaglutide) — known as "semaglutide face" — is a real side effect.

This new market development is opening up an entirely new competitive track for medical aesthetics companies focused on regenerative medicine. A recently listed player in the field of regenerative medicine has clearly stated its intention to target this rapidly growing demand. Its strategy is to leverage regenerative technology to provide filling and tightening solutions for patients experiencing facial volume loss and skin laxity caused by the use of GLP-1 drugs, aiming to claim a share in a market traditionally dominated by established medical aesthetics giants.This trend suggests a possible shift in the landscape of the medical aesthetics industry. Traditional giants whose main businesses are botulinum toxin and hyaluronic acid fillers, such as Allergan Aesthetics (a subsidiary of ABBV), as well as companies specializing in energy-based devices like InMode Ltd. (INMD) and Establishment Labs Holdings Inc. (ESTA), may face new challenges and opportunities. If emerging regenerative technology companies can offer longer-lasting and more natural volume restoration solutions, they may attract a large number of consumers seeking "repair" rather than mere "enhancement."Market analysis points out that the "semaglutide face" phenomenon is spawning not only new therapeutic demands but also a potential cross-growth market. It directly channels the vast user base of weight-loss drugs into the field of medical aesthetics, bringing incremental customers to the entire industry. Whether companies can seize this opportunity—unexpectedly created by pharmaceutical side effects—will be a key test of their innovation and market responsiveness.